Skip to main content
OpenTrials
Completed

NCT Number: NCT05628584

High FODMAP Diet With Metformin in preDM

This is a prospective, double blinded, randomised cross over feeding trial examine high or low FODMAP diet in combination with metformin on postprandial glucose responses and gastrointestinal tolerability and gut microbiota profiles.

The trial will compare high or low FODMAP diet, each of 10 days duration in combination with 5 days metformin, separated by a washout period of at least 2 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Prince of Wales Hospital

Shatin, Hong Kong

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-70 years
  • Body mass index 18 to 40 kg/m 2
  • Prediabetes defined as impaired fasting PG 5.6-6.9 mmol/l and/or impaired glucose tolerance with 2-hour PG 7.8-11.1 mmol/l on 75g oral glucose tolerance test (OGTT) and/or HbA1c 5.7-6.4% at screening

Exclusion criteria

  • Currently pregnant, lactating, as demonstrated by a positive pregnancy test at screening or planning pregnancy
  • Known current diabetes
  • Current or previous use of glucose-lowering or weight loss drugs in 3 months prior to screening
  • Concurrent participation in other weight loss or lifestyle intervention programmes
  • Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
  • Recent intake of prebiotic/probiotic or antibiotic, immunosuppressants (within 8 weeks of randomisation)
  • Extensive skin changes/diseases that preclude wearing the FGM on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).
  • Known uncontrolled thyrotoxicosis
  • Known vitamin B deficiency
  • Known irritable bowel syndrome or gastrointestinal disorders
  • Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2 at screening
  • Current use of steroids
  • Have a known allergy to medical-grade adhesives
  • Known current or recent alcohol or drug abuse
  • Hypersensitivity to metformin
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma within 3 months of randomisation
  • Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.
  • An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).
  • Participants who are on a vegetarian or vegan diet as their habitual diet at screening.
  • Participants with clinically significant food allergy to components of the study diet

Treatment and study plan

High FODMAP diet with metformin

Combination Product

Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period

Low FODMAP diet with metformin

Combination Product

Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period

Primary outcomes

  1. Differences in postprandial glycemia

    Time frame: 10 days

    incremental area under curve on continuous glucose monitoring post meal

Secondary outcomes

  1. Glucose response to 75g oral glucose tolerance test

    Time frame: 10 days

    fasting and postchallenge plasma glucose

  2. Insulin response to 75g oral glucose tolerance test

    Time frame: 10 days

    insulin levels

  3. Change in alpha diversity of gut microbiota

    Time frame: 10 days

    Changes in alpha diversity in gut microbiota

  4. Change in beta diversity of gut microbiota

    Time frame: 10 days

    Changes in beta diversity in gut microbiota

  5. Body weight

    Time frame: 10 days

    Differences in body weight between arms

  6. Gastrointestinal symptoms

    Time frame: 10 days

    Measured on visual analogue scale 1-10 for each item, higher score indicates worse symptoms

Sponsors and collaborators

Lead sponsor

Elaine Chow

Other

Collaborators

  • Merck KGaA, Darmstadt, Germany

Registry information

Official study title

The Impact of High or Low FODMAP Diets on Postprandial Glucose Response and Gut Microbiota in Individuals With Prediabetes Treated With Metformin: A Randomized Crossover Controlled-Feeding Trial

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Nov 28, 2022
Registry last updated
Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.